To the editor:

SARS-CoV-2 virus induces symptoms of variable severity; some patients only have mild illness whereas other rapidly become critically ill progressing to an acute respiratory distress syndrome (ARDS). This critical state of the disease supports the immediate relevance for the development of protective therapeutics against SARS-CoV-2 but requires fundamental knowledge concerning adaptive immune responses induced by the virus. Therefore we have read with interest the recent findings published by Bo and colleagues describing in the early stage of the disease a positive correlation between T-cells decrease and COVID-19 severity.[@bib0001] However, Thijsen and colleagues demonstrated the presence of specific T-cell responses against S and N proteins few days post onset symptoms in patients with severe pneumonia hospitalized in intensive care unit (ICU).[@bib0002] Although the existence of SARS-CoV-2 specific T-cells has been described,[@bib0002] ^,^ [@bib0003] the frequency and the intensity of SARS-CoV-2 specific T-cell responses among mild illness and severe pneumonia convalescent COVID-19 patients remains to be investigated.

In this prospective study, 60 patients who had COVID-19 were enrolled in a two cohorts study that were entitled mild illness (*n* = 30) and severe pneumonia (*n* = 30) at least 21 days after the first symptoms of COVID-19 (38 days \[21--53\]; [Table 1](#tbl0001){ref-type="table"} ). The aim was to describe adaptive immune responses in COVID-19 convalescent patients according to their disease severity. All patients were considered as cured at the time of inclusion. Patients' characteristics are detailed in [Table 1](#tbl0001){ref-type="table"}. The mean age was 54.1 +/- 17.4, and 30 patients (50.0%) were male. Patients with severe pneumonia had more diabetes (20.0% vs 0.0%, *P*\<0.001), hypertension (47.0% vs 6.7%, *P*\<0.001), higher body mass index (24.1 vs 20.5, *P*\<0.001), they were older (68.3 vs 39.8, *P*\<0.001) and more frequently male (77.0% vs 23.0%) *P*\<0,001) as previously described.[@bib0004] Interestingly, patients with severe pneumonia had also more fever (86.7% vs 43.3%, *P*\<0.001), dyspnea (86.7% vs 6.7% *P*\<0.001) and less myalgia (16.7% vs 60.0%, *P*\<0.001). Among patients who presented severe pneumonia, 23 (76.7%) were hospitalized in ICU for acute respiratory distress related to COVID-19. No patient died during the study period. The identification of SARS-CoV-2 specific T-cell responses was performed using *ex vivo* ELISpot assays that measure IFNᵧ produced by activated T-cells ([Fig. 1](#fig0001){ref-type="fig"} A). Median intensities for CoV-N T-cells responses were higher (*P* = 0.006) and the one of CoV-S (*P* = 0.056) and CoV-M (*P* = 0.29) tends to be increased in patients with mild illness compared to patients with severe pneumonia (73.0 IFNᵧ spot/3 × 10^5^ cells \[IQR: 39.0--595.0\] vs 33.5 IFNᵧ spot/3 × 10^5^ cells \[IQR: 20.5--75.2\]; 108.5 IFNᵧ spot/3 × 10^5^ cells \[IQR: 46.0--669.0\] vs 50.0 IFNᵧ spot/3 × 10^5^ cells \[IQR: 27.4--100.1\] and 150.5 IFNᵧ spot/3 × 10^5^ cells \[IQR: 43.0--591.8\] vs 66.5 IFNᵧ spot/3 × 10^5^ cells \[IQR: 94.0--178.0\] for CoV-N, CoV-S and CoV-M respectively; [Fig. 1](#fig0001){ref-type="fig"}B). Additionally, T-cells' specificity was analyzed based on IFNᵧ secretion using flow cytometry in thirteen patients from both cohorts (*n* = 6 mild illness patients and *n* = 7 severe pneumonia patients). Specific T-cell responses against S, M and N proteins were mediated by CD8 and CD4T-cells in both cohorts (data not shown). The presence of SARS-CoV-2 specific T-cells in healthy donors (33% for CoV-S and M and 14% for CoV-N) might be explained by the sequence homology between structural proteins from various coronavirus suggesting the existence of cross reactive memory T-cells.[@bib0005] Indeed, high degrees of similarities between coronaviruses and SARS-CoV-2 concerning S, M and N structural proteins have been recently described.[@bib0006] ^,^ [@bib0007] Table 1Characteristics of patients with COVID-19. Comparison between severe pneumonia and mild disease.Table 1VariablesTotal (*n* = 60)Mild disease (*n* = 30)Severe pneumonia (*n* = 30)Univariate P valueMale sex30 (50)7 (23.3)23 (76.7)**\<0.001**Mean age ±SD54.1 (±17.4)39.8 (±11.7)68.3 (±7.59)**\<0.001**Body mass index, mean ±SD22.3 (±4.23)20.5 (±3.72)24.1 (±3.99)**\<0.001**Comorbidities, n (%) Hypertension16 (26.7)2 (6.7)14 (46.7)**\<0.001** Chronic pulmonary disease8 (13.3)1 (3.3)7 (23.3)0.052 Diabetes melitus6 (10)0 (0)6 (20)**0.024** Coronary heart disease1 (1.7)0 (0)1 (3.3)1 Chronic renal insufficiency1 (1.7)0 (0)1 (3.3)1McCabe score Non fatal, n (%)39 (65)28 (93.3)11 (36.7)**\<0.001** Ultimately fatal, n (%)19 (31.7)2 (6.7)17 (56.7) Rapidly fatal, n (%)2 (3.3)0 (0)2 (6.7)Clinical characteristics, n (%) Fever39 (65)13 (43.3)26 (86.7)**\<0.001** Myalgia or arthralgias23 (38.3)18 (60)5 (16.7)**\<0.001** Fatigue44 (73.3)24 (80)20 (66.7)0.24 Headache23 (38.3)15 (50)8 (26.7)**0.063** Diarrhea14 (23.3)3 (10)11 (36.7)**0.015** Dyspnea28 (46.7)2 (6.7)26 (86.7)**\<0.001** Sputum production12 (20)8 (26.7)4 (13.3)0.2Cough40 (66.7)18 (60)22 (73.3)0.27Hospitalisation, n (%)30 (50)030 (100)-- Length of stay, dy mean ±SD26±1526±15--Transfer in ICU, n (%)23 (38.3)023 (76.7)**--** Length of stay, dy mean ±SD19±1219±12--ARDS, n (%)28 (46.7)28 (93.3)Non specific therapy, n (%) Oxygenotherapy30 (50)030 (100)**--** Mechanical ventilation20 (33.3)20 (66.7)-- Neuromuscular blocking agent20 (33.3)20 (66.7)-- Prone positionning17 (28.3)17 (56.7)-- Inhaled nitric oxide2 (3)2 (6.7)-- Vasopressors11 (18.3)11 (36.7)-- Specific therapy, n (%)28 (46.7)028 (93.3)**--** Corticosteroids10 (16.7)10 (33.3)-- Interferon7 (11.7)7 (23.3)-- Lopinavir/ritonavir9 (15)9 (30)-- Hydroxychloroquine12 (20)12 (40)-- Remdesivir4 (6.7)4 (13.3)--Laboratory findings, moy (±SD) Delay first symptom/blood sample, dy med \[min-max\]38 \[21--53\]39 \[27--51\]38 \[21--45\]**0.019** Lymphocyte count (G/L), mean (±SD)2.10 (±0.761)2.29 (±0.565)1.91 (±0.884)**\<0.01**Serology Positive IgG serology, n (%)57 (95)27 (90)30 (100)0.24 Index, mean ±SD6.05 (±2.18)4.92 (±2.40)7.19 (±1.09)**\<0.001**T-cell responses[\*](#tb1fn1){ref-type="table-fn"}, n (%) CEF positivity45/59 (76.3)22/29 (75.9)23/30 (76.7)0.94 COV M positivity44/59 (74.6)17/29 (58.6)27/30 (90)**\<0.01** COV N positivity43/59 (72.9)19/29 (65.5)25/30 (83.3)0.14 COV S positivity33/59 (55.9)11/29 (37.9)22/30 (73.3)**\<0.01**[^1]Fig. 1SARS-CoV-2 specific T-cell responses were increased in mild illness compared to severe pneumonia COVID-19 patients. **A.** PBMC from 21 healthy donors and COVID-19 patients with mild illness (*n* = 29) or severe pneumonia (*n* = 30) were analyzed for SARS-CoV-2 and antiviral-specific T-cell responses by IFNᵧ ELISpot assay. **B.** Intensity of positive SARS-CoV-2 specific immune responses in healthy donors and COVID-19 patients. Mann Whitney test, \*\**P*\>0.001. Median with interquartile range were indicated. **C**. Heatmap showing the positivity or the negativity of the serology index, T-cell immune responses to SARS-CoV-S, M and N proteins for each patients included in the study (online Morpheus software). **D.** Frequency of patients with a specific T-cell response for at least one SARS-CoV-2 proteins (CoV-S, CoV-M or CoV-N) (*P* = 0.0211). **E.** Frequency of mild illness and severe pneumonia patients with specific T-cell responses for simultaneously CoV-S, CoV-M and CoV-N proteins (*P* = 0.0191). **F.** Frequency (%) of positive antiviral memory CD8T-cell responses for healthy donors, mild illness and severe pneumonia COVID-19 convalescent patients. Healthy donors were represented by light gray points. COVID-19 convalescent patients were respectively represented by black point (mild illness) and red points (severe pneumonia). PBMC: Peripheral Blood Mononuclear Cells.Fig 1

Beyond specific cellular responses, typical humoral responses to acute viral infection are wildly induced in COVID-19 patients.[@bib0008] Zhao et al. showed that the seroconversion rate and antibody levels increased rapidly during the first two weeks with a cumulative seropositive rate of 50.0% on the 11th-day and 100% on the 39th-day. High titers of IgG antibodies detected by Enzyme immunoassays have been shown to positively correlate with neutralizing antibodies. [@bib0008] ^,^ [@bib0009] In this study, the median serology index of severe pneumonia patients was equal to 7.19 S/CO \[IQR: 6.1--8.28\] and was significantly higher than the one of mild illness patients that was equal 4.92 S/CO \[IQR: 2.52--7.32\], (*P\<*0.001) ([Table 1](#tbl0001){ref-type="table"}). A heatmap was then generated, using the online Morpheus software (<https://software.broadinstitute.org/morpheus/>), to correlate all immunological parameters investigated (serology index and T-cell immune responses to SARS-CoV-S, M and N proteins) **(** [Fig. 1](#fig0001){ref-type="fig"}C). We observed that all patients with severe pneumonia had a positive serology index and most of them had at least one specific cellular response for SARS-CoV-2 proteins (28 out of 30). In contrast, patients with mild illness had less specific cellular responses (20 out of 29) than severe pneumonia patients (*P* = 0.0211) ([Fig. 1](#fig0001){ref-type="fig"}D). Among mild illness patients, three had a negative serology index ([Fig. 1](#fig0001){ref-type="fig"}C). Specific T-cell responses for S, M and N proteins were simultaneously shown for 70.0% of severe pneumonia patients while only for 37.9% of mild illness patients (*P* = 0.0191) ([Fig. 1](#fig0001){ref-type="fig"}E). Of note, levels of T-cell responses were not influenced by previous exposition to a specific COVID-19 treatment (Lopinavir/ritonavir; Interferon-Beta-1A; Hydroxychloroquine and Remdesivir) (data not shown). We notice that despite a lower intensity of response in terms of INFᵧ secretion ([Fig. 1](#fig0001){ref-type="fig"}B), patients with severe pneumonia had frequencies of responses clearly distinct from the one of mild illness patients.

Another immunological issue is the potential impact of SARS-CoV-2 virus mediated infection on pre-existing memory T-cell repertoire against common viruses. To address this issue, we concomitantly measured in all the COVID-19 patients the reactivity against common viruses (Cytomegalo-, Epstein-Barr and Flu-virus: CEF) using IFNᵧ ELISpot assay. Median intensities of CEF specific T-cell responses in healthy donors, mild illness and severe pneumonia patients were similar in terms of intensities (respectively 144.0 IFNᵧ spot/3 × 10^5^ cells \[IQR: 48.8--665.9\], 88.2 IFNᵧ spot/3 × 10^5^ cells \[IQR: 42.8--218.6\] and 116.0 IFNᵧ spot/3 × 10^5^ cells \[IQR: 67.5--179.0\]) and frequencies (respectively 83.0%, 76.0% and 77.0%) ([Fig. 1](#fig0001){ref-type="fig"}F).

The present study shows the existence of both specific SARS-CoV-2 cellular and humoral responses depending on COVID-19 severity. The presence of potent adaptive immunity even in patients who underwent severe pneumonia sustain the rationale for the development of protective therapeutics against SARS-CoV-2 virus.
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[^1]: ELISpot was not performed for one patient, ARDS = Acute Respiratory distress syndrome.
